leisure time -WSS

leisure time

author：comprehensive 2025-09-30 11:57:36 - browse：8

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

knowledge

WSS

How housing is health care on Long Island

There's no autism epidemic. It's an autism diagnosis epidemic

FDA panel endorses Alnylam’s heart drug — after picking it apart

WATCH: Why do bright lights make us see spots?

Food as medicine: Medically tailored meals may get standardized

New weight loss drugs vying to be the next Wegovy or Mounjaro

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Diverse clinical trials: Why aren’t we there yet?

Alkermes shareholders re

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Virginia high school admissions case could be legal follow

FDA approves updated Covid vaccines

As demand for Covid shots wanes, Moderna seeks its next success

Scientists boost immune system in aging mice by making it youthful

New air purifier tech could be key to improving indoor air quality

Washington mulls new rules to avert another Change Healthcare

focus

How medical schools plan to diversify without affirmative action

Telehealth for opioid use disorder is lifesaving

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Steward Health Care has deal to sell doctor network to UnitedHealth

Regeneron agrees to White House price limits on anti

Long Covid needs a new name — and a new frame

focus

explore

knowledge

Wikipedia